Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prevail: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Chemotherapy-naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Next Previous
Search
Trial Profile

Prevail: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Chemotherapy-naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PREVAIL
  • Sponsors Medivation; Pfizer

    • Most Recent Events

    • 16 May 2023 Results of meta-analysis from PROpel , PREVAIL and COU-AA-302 (AA) treatment arms, Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer, published in the European Urology Open Science
    • 25 May 2022 Results of post hoc, pooled, retrospective analysis from AFFIRM, PREVAIL and PROSPER examining the association of statin and metformin on radiographic progression-free survival , metastasis-free survival, toxicity and overall survival, published in the European Journal of Cancer
    • 21 Sep 2020 Results assessing Impact of enzalutamide on patient-reported fatigue from ARCHES, PROSPER, PREVAIL, and AFFIRM presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top